THANK YOU FOR SUBSCRIBING
The company's CorVent Single-Use Ventilator is designed to meet each patient's respiratory needs in an easy plug and play set-up with built-in safeguards. Its single patient design facilitates superior infection control with integrated filters to protect healthcare providers, staff, and patients
Fremont, CA: Coridea portfolio company CorVent Medical closed a USD 4.5 million seed funding round led by the prominent European life sciences venture capital firm Sofinnova Partners with participation from Redmile Group, Exor Seeds, Genesis Medtech Group, The Deerfield Foundation, The Pagliuca Family Office, and Accel Founder Jim Swartz. The seed financing was raised to support the commercialization of the first single-use, critical care ventilator that will enable rapid and affordable deployment with superior infection control.
"The COVID-19 pandemic has highlighted a significant need for emergency-use ventilators that can be rapidly deployed to enable on-demand, critical care ventilation," stated Antoine Papiernik, Managing Partner at Sofinnova Partners. "CorVent has created an elegant yet simple, single-use solution for emergency preparedness that can be stored for long periods of time without the expense and delay of complicated service contracts. We are proud to partner with this proven team to bring a much-needed solution to the market."
Proceeds from the investment round will be used by the company to finalize regulatory filings under the U.S. Food and Drug Administration's Emergency Use Authorization (EUA) Act, to upon approval launch the CorVent™ Single-Use Ventilator, and to support future development of next-generation lifesaving devices for respiratory insufficiency. The company's CorVent Single-Use Ventilator is designed to meet each patient's respiratory needs in an easy plug and play set-up with built-in safeguards. Its single patient design facilitates superior infection control with integrated filters to protect healthcare providers, staff, and patients.
"Our product is unique in that it is the only single-use, critical care ventilator that extends capacity when needed most," commented Mark Gelfand, CEO of CorVent. "Whether it is in response to a pandemic or to address an underserved market, our single-use ventilator enables hospitals, states, and countries to cost-effectively and efficiently address respiratory insufficiency so healthcare providers can immediately focus on critical patient needs." Delivering critical care ventilation at a moment's notice, the CorVent™ Single-Use Ventilator complements existing products during hospital shortages or in underserved markets.